Jobs
-
The FDA has issued a clinical hold on Altimmune’s IND for its AdCOVID intranasal COVID-19 vaccine candidate, the company said. Altimmune submitted the IND to the agency in November 2020. According to the company, the… Read more . . .
-
Menarini will pay Glenmark an undisclosed amount up front plus milestone payments for exclusive rights to market Ryaltris olopatadine/mometasone furoate nasal spray in 33 European countries, Ryaltris developer Glenmark has announced. Glenmark will be continue… Read more . . .
-
According to Polyphor, the UK’s MHRA has authorized a Phase 1 study of the company’s murepavadin inhalation solution, which the company is developing for the treatment of Pseudomonas aeruginosa lung infections in cystic fibrosis patients.… Read more . . .
-
Swedish DPI developer Iconovo announced that Monash University has acquired exclusive global rights for the use of Iconovo’s ICOone single dose DPI for delivery of Monash’s inhaled oxytocin for the prevention of postpartum hemorrhage. The… Read more . . .
-
Several months after acquiring the rights to TNX-1900 oxytocin nasal spray for the treatment of migraine headaches from Trigemina, Tonix Pharmaceuticals announced that it has acquired an exclusive license to technology from the University of… Read more . . .
-
Catalent will supply development services for an intranasal formulation of Novan’s berdazimer sodium for COVID-19, the companies said. Berdazimer sodium is a nitric oxide-releasing polymer based on Novan’s Nitricil platform, and the company is developing… Read more . . .
-
Oyster Point Pharma has announced its submission of a 505(b)(2) NDA for its OC-01 varenicline nasal spray for the treatment of dry eye disease. In May 2020, Oyster Point announced positive results from the the… Read more . . .
-
Johnson & Johnson spinout PrEP Biopharm said that it is ready to initiate a real-world trial of its PrEP-001 intranasal “viral RNA surrogate” against common respiratory viruses after the successful completion of a toxicology study… Read more . . .
-
Hikma Pharmaceuticals announced that the FDA has approved 100 mcg/50 mcg and 250 mcg/50 mcg doses of the company’s fluticasone propionate / salmeterol DPI (VR315), a generic version of Advair Diskus and that the company… Read more . . .
-
By the time DDL 2020 began its live “Christmas lectures” on December 9, more than 1,450 delegates had registered for the meeting. Although the live presentations concluded on December 11, there are still benefits to… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland